Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.

Ohtake T, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Kobayashi S.

Hypertens Res. 2008 Mar;31(3):387-94. doi: 10.1291/hypres.31.387.

PMID:
18497456
2.

Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.

Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.

Am J Nephrol. 2000 Sep-Oct;20(5):373-9.

PMID:
11092994
4.

Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.

Mahmood J, Khan F, Okada S, Kumagai N, Morioka T, Oite T.

Kidney Int. 2006 Nov;70(9):1591-8. Epub 2006 Sep 20.

5.

Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression.

Mii A, Shimizu A, Masuda Y, Ishizaki M, Kawachi H, Iino Y, Katayama Y, Fukuda Y.

Lab Invest. 2009 Feb;89(2):164-77. doi: 10.1038/labinvest.2008.128. Epub 2009 Jan 12.

6.

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators.

Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. doi: 10.1093/ndt/gfn230. Epub 2008 May 1.

7.

Urinary protein markers predict the severity of renal histological lesions in children with mesangial proliferative glomerulonephritis.

Li Y, Wang J, Zhu X, Feng Q, Li X, Feng X.

BMC Nephrol. 2012 May 20;13:29. doi: 10.1186/1471-2369-13-29.

9.

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.

Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC; HKVIN Study Group.

Am J Kidney Dis. 2006 May;47(5):751-60.

PMID:
16632013
10.

Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.

Mori-Takeyama U, Minatoguchi S, Murata I, Fujiwara H, Ozaki Y, Ohno M, Oda H, Ohashi H.

Clin Exp Nephrol. 2008 Feb;12(1):33-40. doi: 10.1007/s10157-007-0013-6. Epub 2008 Jan 5.

PMID:
18175062
11.

Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.

Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.

Nephrology (Carlton). 2015 Feb;20(2):77-84. doi: 10.1111/nep.12359.

PMID:
25358874
12.

Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.

Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y.

J Nephrol. 2003 Nov-Dec;16(6):841-9.

PMID:
14736011
13.

DNA fragmentation in chronic glomerulonephritis: an immunohistological analysis.

Ott U, Aschoff A, Pocock J, Fünfstück R, Jirikowski G, Stein G, Wolf G.

Nephron Clin Pract. 2007;105(1):c18-28. Epub 2006 Nov 15.

PMID:
17114899
14.

Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.

Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.

Hypertens Res. 2004 Dec;27(12):963-70.

15.

Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.

Soleymanian T, Najafi I, Salimi BH, Broomand B.

Ren Fail. 2011;33(6):572-7. doi: 10.3109/0886022X.2011.585001.

PMID:
21663387
16.

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.

Am J Hypertens. 2007 Nov;20(11):1195-201.

PMID:
17954367
17.

Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy.

Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K.

Hypertens Res. 2008 Sep;31(9):1711-7. doi: 10.1291/hypres.31.1711.

PMID:
18971549
18.

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.

Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18.

PMID:
18423812
19.

Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.

Zoja C, Abbate M, Corna D, Capitanio M, Donadelli R, Bruzzi I, Oldroyd S, Benigni A, Remuzzi G.

Am J Kidney Dis. 1998 Mar;31(3):453-63.

PMID:
9506682
20.

[Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].

Iimura O, Kusano E, Tanba K, Yanagiba S, Amemiya M, Ando Y, Honma S, Muto S, Asano Y.

Nihon Jinzo Gakkai Shi. 2003 Jul;45(5):439-44. Japanese.

PMID:
14509219
Items per page

Supplemental Content

Write to the Help Desk